Madrigal Pharmaceuticals MDGL reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus ...
Conshohocken’s Madrigal inks a $4B-plus global deal to expand its MASH drug pipeline beyond blockbuster Rezdiffra.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results